Nutraceutical Products

Ananda Scientific, Inc., through its manufacturing subsidiary Anano Technologies, Inc., currently produces the following products.

HAS YOUR TECHNOLOGY BEEN VALIDATED FOR THC OR ANY OTHER CANNABINOIDS?

Cannabidiol (CBD) rather than tetrahydrocannabinol (THC) has been a major focus to date, for our enhancement technology, herein termed “Liquid Structure”. Making Liquid Structure THC constructs, albeit rapidly doable, has not been a priority.

 

About Liquid Structure Technology. A brief review of patented Liquid Structure technology is first in order. Liquid Structure constructs may be rapidly configured for a specific cannabinoid and otherwise for a bevy of plant-derived substances. The technology centers about using incredibly-small vessels (15-nm in size) highly specific (with high affinity) as to what target substances are contained inside (a particular vessel will work only with certain molecules and not others) for amplifying or intensifying bioavailability. Bioavailability refers to the ease with which a substance can reach the bloodstream after its administration (e.g., taken by mouth) and thus becomes available to its sites of action.

 

With Liquid Structure technology, the relationship between a target substance (the substance chosen for delivery into the bloodstream) and its corresponding Liquid Structure construct can be explained using a “lock and key” analogy. The “lock” is a Liquid Structure construct and the “key” is a target substance like CBD. Only the correctly-configured key (CBD) fits into the lock (Liquid Structure construct), thus the above-mentioned high specificity.

 

The fluidity, adhesive and viscoelastic properties of Liquid Structures work by assisting a target substance rapidly and efficaciously across the mucosal membranes of the small intestine to the bloodstream. An emptied Liquid Structure construct (i.e., minus the target substance) stays in the intestinal lumen where it subsequently falls apart. These disassociated chemical moieties are assimilated as food.

 

The Capacity of Liquid Structure Technology. Patented Liquid Structure technology may be used with virtually any plant-derived chemistry and not just cannabinoids like THC and CBD. For example, we have successfully done this with curcumin (the active component of turmeric, it inhibits the activity of enzymes related to inflammation, cyclooxygenase and 5-lipooxygenase), resveratrol (an anti-oxidant in grapes and pomegranates), docosahexaenoic acid (DHA, an omega-3 fatty acid), boswellic acid (an anti-oxidant from frankincense) and ursolic acid (an anti-inflammatory and anti-fungal agent from apples, basil, cranberries, rosemary, lavender, oregano and more) into the Liquid Structure format. Regarding curcumin, its aqueous solubility was increased an unprecedented 400X with our Liquid Structure enhancement technology.

 

Liquid Structure Enhancement of THC. Laboratory studies show that creating an enhanced THC or doing the same with cannabinoids like cannabigerol (CBG) or tetrahydrocannabivarin (THCV) can be achieved in a matter of days. Afterward, it is then just a matter of optimization.

 

However, whether we may want to make a much more potent THC at the present time is a question. Consequent to its enhancement, THC ensconced in Liquid Structure chemistry, with great likelihood, would likely have greater psychoactive activity than does regular or non-treated THC. Making certain that a preparation with elevated potency is judiciously or correctly used is a necessity.

I AM VERY INTERESTED IN KNOWING MORE ABOUT THE FOOD/DIETARY INGREDIENT POTENTIAL OF YOUR TECHNOLOGY.

DO YOU KNOW IF YOUR TECHNOLOGY WOULD PROTECT CBD FROM OXIDATION?

GIVEN ITS NANOTECHNOLOGY NATURE DO YOU HAVE ANY INDICATION IT WOULD BE ACCEPTED BY REGULATORY AGENCIES IN THE US AND CANADA AS A SAFE FOOD/DIETARY SUPPLEMENT INGREDIENT? HOW ABOUT THE SAME FOR THE PHARMACEUTICAL PRODUCT?

WOULD YOU BE ABLE TO SHARE INFORMATION ON THE EXTRACTION TECHNOLOGY?

WHEN WE SPOKE YOU WERE SEEKING AN INVESTMENT OR A POTENTIAL PARTNER TO ROLL THE CLINICAL PRODUCT INTERNATIONALLY, CORRECT? WOULD THERE BE ANY OPPORTUNITIES OUTSIDE CLINICAL?